for his contribution to advising on the control of the foot-and-mouth epidemic in the UK in 2001. His current research focus is on the use of models as contingency planning tools for emerging infections (pandemic influenza in particular) and bioterrorism.
Bruce Gellin, MD
Dr. Gellin is the Director of the National Vaccine Program Office (NVPO) in the US Department of Health and Human Services. Before joining the NVPO, Dr. Gellin was the director of the National Network for Immunization Information, an organization he founded to be a resource for up-to-date, authoritative information about vaccines and immunizations. Dr. Gellin has had broad experience in public health aspects of infectious diseases and has held positions at the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention (CDC), the Rockefeller Foundation, and the Johns Hopkins University School of Public Health.
Julie Louise Gerberding, M.D., M.P.H.
Dr. Gerberding is the Director of the Centers for Disease Control and Prevention (CDC) and the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR). Before becoming CDC Director and ATSDR Administrator, Dr. Gerberding was Acting Deputy Director of National Center for Infectious Diseases (NCID), where she played a major role in leading CDC’s response to the anthrax bioterrorism events of 2001. She joined CDC in 1998 as Director of the Division of Healthcare Quality Promotion, NCID, where she developed CDC’s patient safety initiatives and other programs to prevent infections, antimicrobial resistance, and medical errors in healthcare settings. Prior to coming to CDC, Dr. Gerberding was a University of California at San Francisco (UCSF) faculty member and directed the Prevention Epicenter, a multidisciplinary research, training, and clinical service program that focused on preventing infections in patients and their healthcare providers. Dr. Gerberding is an Associate Clinical Professor of Medicine (Infectious Diseases) at Emory University and an Associate Professor of Medicine (Infectious Diseases) at UCSF.
Jesse Goodman, MD.
Dr. Goodman serves as the Director of FDA’s Center for Biologics Evaluation and Research (CBER). Dr. Goodman joined FDA's Office of the Commissioner in 1998, where he directed the U.S. government's Interagency Task Force on Antimicrobial Resistance. He later moved to CBER, where he has been active in a wide variety of clinical and public health issues including bioterrorism preparedness and response, product development, human subject protection, and blood and vaccine safety. He is a virologist who is board certified in internal medicine, oncology, and infectious diseases. Educated at Harvard, he earned an M.D. from Albert Einstein, and did residency and fellowship training at the University of Pennsylvania and UCLA.
Honorable Michael O. Leavitt
Secretary Leavitt was sworn in as the 20th Secretary of the U.S. Department of Health and Human Services on January 26, 2005. As secretary, he leads national efforts to protect the health of all Americans and provide essential human services to those in need. He manages the largest civilian department in the federal government, with more than 66,000 employees and a budget that accounts for almost one out of every four federal dollars. Prior to his current service,